PE20061246A1 - METHOD OF TREATMENT AND PREVENTION - Google Patents
METHOD OF TREATMENT AND PREVENTIONInfo
- Publication number
- PE20061246A1 PE20061246A1 PE2005001384A PE2005001384A PE20061246A1 PE 20061246 A1 PE20061246 A1 PE 20061246A1 PE 2005001384 A PE2005001384 A PE 2005001384A PE 2005001384 A PE2005001384 A PE 2005001384A PE 20061246 A1 PE20061246 A1 PE 20061246A1
- Authority
- PE
- Peru
- Prior art keywords
- odiparcil
- administered
- refers
- heparin
- treatment
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title 1
- JRHNIQQUVJOPQC-AQNFWKISSA-N 4-methyl-7-[(2r,3r,4s,5s)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1SC[C@@H](O)[C@H](O)[C@H]1O JRHNIQQUVJOPQC-AQNFWKISSA-N 0.000 abstract 3
- 229950005036 odiparcil Drugs 0.000 abstract 3
- 102000004032 Heparin Cofactor II Human genes 0.000 abstract 2
- 108090000481 Heparin Cofactor II Proteins 0.000 abstract 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN METODO PARA TRATAR O PREVENIR TRANSTORNOS TROMBOEMBOLICOS QUE COMPRENDE LA ADMINISTRACION DE 4-METIL-2-OXO-2H-1-BENZOPIRAN-7-IL-5-TIO-ß-D-XILOPIRANOSIDO (ODIPARCIL) CUYO MECANISMO DE ACCION IMPLICA UNA BIOSINTESIS INCREMENTADA DE LOS GLUCOSAMINOGLUCANOS (GAG)Y LA POSTERIOR ELEVACION DE LA ACTIVIDAD ANTI-IIa VIA EL COFACTOR II DE LA HEPARINA (HCII). SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ODIPARCIL QUE SE ADMINISTRA EN UNA CANTIDAD DE 125mg A 1g POR DIA DE PREFERENCIA 250 mg A 1g, 500 mg A 1g ENTRE OTROS, ADMINISTRADO DE PREFERENCIA CADA 12 HORAS. EL TRATAMIENTO COMPRENDE ADMINISTRAR UN CANTIDAD EFICAZ DE ODIPARCIL Y ASPIRINA O UNA HEPARINA LOS CUALES SE ADMINISTRAN INDEPENDIENTEMENTEIT REFERS TO A METHOD TO TREAT OR PREVENT THROMBOEMBOLIC DISORDERS THAT INCLUDE THE ADMINISTRATION OF 4-METHYL-2-OXO-2H-1-BENZOPYRAN-7-IL-5-THIO-ß-D-XYLOPYRANOSIDE (ACYPARCIL ODIPARCIL) CUYO IT INVOLVES AN INCREASED BIOSYNTHESIS OF GLUCOSAMINOGLUCANES (GAG) AND THE SUBSEQUENT ELEVATION OF ANTI-IIa ACTIVITY VIA THE HEPARIN COFACTOR II (HCII). IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING ODIPARCIL THAT IS ADMINISTERED IN AN AMOUNT OF 125mg TO 1g PER DAY OF PREFERENCE 250mg TO 1g, 500mg TO 1g AMONG OTHERS, ADMINISTERED PREFERABLY EVERY 12 HOURS. THE TREATMENT INCLUDES ADMINISTERING AN EFFECTIVE AMOUNT OF ODIPARCIL AND ASPIRIN OR A HEPARIN, WHICH ARE ADMINISTERED INDEPENDENTLY
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63215304P | 2004-12-01 | 2004-12-01 | |
| US69172805P | 2005-06-17 | 2005-06-17 | |
| US72169105P | 2005-09-29 | 2005-09-29 | |
| US72471005P | 2005-10-07 | 2005-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061246A1 true PE20061246A1 (en) | 2006-11-08 |
Family
ID=36565378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001384A PE20061246A1 (en) | 2004-12-01 | 2005-11-29 | METHOD OF TREATMENT AND PREVENTION |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR053789A1 (en) |
| PE (1) | PE20061246A1 (en) |
| TW (1) | TW200635580A (en) |
| UY (1) | UY29237A1 (en) |
| WO (1) | WO2006060647A1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2801055B1 (en) * | 1999-11-17 | 2002-02-08 | Fournier Ind & Sante | BETA-D-5-THIOXYLOSE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE |
-
2005
- 2005-11-29 TW TW094141796A patent/TW200635580A/en unknown
- 2005-11-29 PE PE2005001384A patent/PE20061246A1/en not_active Application Discontinuation
- 2005-11-29 UY UY29237A patent/UY29237A1/en unknown
- 2005-11-29 AR ARP050104989A patent/AR053789A1/en not_active Application Discontinuation
- 2005-12-01 WO PCT/US2005/043602 patent/WO2006060647A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| UY29237A1 (en) | 2006-05-31 |
| TW200635580A (en) | 2006-10-16 |
| AR053789A1 (en) | 2007-05-23 |
| WO2006060647A1 (en) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010349A2 (en) | BIFUNCTIONAL COMPOUNDS TO DEGRADE BTK THROUGH THE UBIQUITIN-PROTEOSOMA PATHWAY | |
| AR043188A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF PROINFLAMATORY CYTOKINS | |
| AR026610A1 (en) | A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | |
| AR044007A1 (en) | METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| GT200300075BA (en) | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND PROCEDURES FOR THEIR PREPARATION (FRACTIONARY PATENT NO. 2 OF THE APPLICATION NO. PI-20030075) | |
| AR068185A1 (en) | COMPOSITIONS OF LAMOTRIGIN ORAL DISINTEGRATION TABLETS | |
| CY1118017T1 (en) | SURVIVING DEFICIENCY AND THE DEFICIENCY OF Vitamin D WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3 | |
| AR109170A2 (en) | ACID SPHINGOMYELINASE FOR USE IN THE PREVENTION OR TREATMENT OF NIEMANN-PICK A OR B DISEASE IN A PATIENT | |
| AR047841A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE-INFLAMMATORY DISORDERS | |
| CY1116747T1 (en) | Combination therapy for the therapeutic treatment of Protein Deficiency Disorders | |
| AR062760A1 (en) | ADMINISTRATION OF DIPEPTIDILPETIDASA INHIBITORS | |
| CY1110495T1 (en) | USE OF A NMDA RECEPTOR RECEPTOR FOR INTERVENTION THERAPY Caused by COG | |
| CO6150188A2 (en) | USE OF TEENCTEPLASA TO TREAT AN ACUTE ISCHEMICAL ICTUS | |
| CO6280475A2 (en) | METHOD TO TREAT THE DEFICIENCY OF VITAMIN B12 | |
| BR112023021131A2 (en) | ESSENTIAL TREMOR TREATMENT | |
| EE200200565A (en) | Combination therapy with vascular adverse effects | |
| UY32109A (en) | METHODS TO USE AMINOPIRIDINE SUSTAINED RELEASE COMPOSITIONS | |
| AR110800A1 (en) | METHODS TO INCREASE 2'-DEOXYURIDINE (dUrd) IN BLOOD PLASMA AND THE INHIBITION OF THYMIDYLATE SYNTHASE | |
| RU2015119377A (en) | DRUG FORMS FOR QUICK COUPLING OF PARKINSON'S DISEASE | |
| PE20130147A1 (en) | PHARMACEUTICAL COMBINATION OF THEOBROMINE AND A NON-OPIOID ANTITUSSIVE AGENT | |
| BRPI0509710A8 (en) | CONTROLLED RELEASE FORMULATION FOR ORAL ADMINISTRATION OF HMG-COA REDUTASE INHIBITOR AND METHOD FOR PREPARING IT | |
| AR048318A1 (en) | ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA | |
| WO2023069514A9 (en) | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway | |
| PE20061246A1 (en) | METHOD OF TREATMENT AND PREVENTION | |
| BR0108261A (en) | Use of mirtazapine, method of treating a sleep disorder in an individual, and patient kit for the treatment of sleep disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |